載入...
Arsenic Trioxide for Treating Acute Promyelocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
The National Institute for Health and Care Excellence (NICE) invited Teva, the company manufacturing arsenic trioxide (ATO; tradename Trisenox(®)), to submit evidence for the clinical and cost effectiveness of ATO for untreated and relapsed or refractory acute promyelocytic leukaemia (APL). Kleijnen...
Na minha lista:
| 發表在: | Pharmacoeconomics |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Springer International Publishing
2018
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6559128/ https://ncbi.nlm.nih.gov/pubmed/30426463 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40273-018-0738-y |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|